Who is sponsoring NCT05596994?

NCT05596994 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT05596994?

Interventions in NCT05596994: Lighting Intervention Therapy, Sham LIT.

What condition does NCT05596994 study?

NCT05596994 studies Mild Cognitive Impairment, Alzheimer's Disease.

Is NCT05596994 still recruiting?

NCT05596994 is currently completed. Last updated 29 June 2025.

Last reviewed 2025-06-29 · How we verify

NCT05596994

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

Completed NA Last updated 29 June 2025

What this trial tests

NA trial testing Lighting Intervention Therapy in Mild Cognitive Impairment in 24 participants. Completed in 30 May 2025.

Timeline

28 February 2023

Primary endpoint
30 May 2025

30 May 2025

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	24
Start date	28 February 2023
Primary completion	30 May 2025
Estimated completion	30 May 2025
Sites	1 location across United States

Drugs / interventions tested

Lighting Intervention Therapy
Sham LIT

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 50 to 85, any sex, with Mild Cognitive Impairment or Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to investigate the effect of a light treatment on sleep, memory and brain function. In people with mild cognitive impairment (MCI) and Alzheimer's disease, sleep-wake disturbance is evident in up to 60% of patients. This can be caused by disruption of circadian rhythms and may affect our health and well-being. Circadian rhythms are the natural cycle of physical, mental, and behavior changes that the body goes through in a 24-hour cycle. Circadian rhythms are mostly affected by light and darkness and are controlled by a small area in the middle of the brain. They can affect sleep, body temperature, hormones, appetite, and other body functions. The circadian system plays an important role in the body and can affect sleep and brain function. The results of the research would help develop light-delivery methods to improve sleep and memory in patients with mild cognitive impairment (MCI) and Alzheimer's disease who typically spend a significant amount of time indoors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer's disease.
Morrone CD, Raghuraman R, Hussaini SA, Yu WH. · · 2023 · cited 40× · PMID 37085942 · DOI 10.1186/s13024-023-00617-4

Verify or expand the search:

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05596994 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 29 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05596994.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing